首页> 外文学位 >In-vitro Evaluations and Physical Characterizations of a Single Solid Dispersion Powder of Diltiazem Hydrochloride for the Development of Multiple Strengths Controlled Release Dosage Forms of the Drug.
【24h】

In-vitro Evaluations and Physical Characterizations of a Single Solid Dispersion Powder of Diltiazem Hydrochloride for the Development of Multiple Strengths Controlled Release Dosage Forms of the Drug.

机译:盐酸地尔硫卓单一固体分散体粉末的体外评估和物理特性,用于开发药物的多种强度控制释放剂型。

获取原文
获取原文并翻译 | 示例

摘要

Diltiazem hydrochloride is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist) Diltiazem is frequently used drug to treat hypertension (high blood pressure), angina (chest pain), and certain heart rhythm disorders. Controlled release formulations based on various technologies are currently available for once-a-day therapy. This study was undertaken to investigate the possibility of applying Solid Dispersion approach for developing controlled release formulations of this drug. Various rate-controlling polymers were evaluated in developing a single solid dispersion powder suitable for use in the formulation of multiple strengths dosage forms of the drug.;Different Solid Dispersions were prepared by solvent evaporation technique using single and multiple carrier systems. Samples equivalent to 120mg, 240mg and 360 mg of drug were evaluated for their in vitro drug release profiles according to the USP Dissolution Apparatus I. The Dissolution studies were conducted for 2 and 24 hours using SGF and SIF as the dissolution media respectively. A physical mixture of optimum formulation was also included for comparison purposes. The dispersion sample was aged for 1 month at various temperatures and evaluated for the drug release. In addition, the formulation was enlarged and studied for its stability to use on a commercial scale. Physical Studies including Differential Scanning Calorimetry, XRD and FTIR were carried out to characterize the Solid Dispersions.;Among all the samples evaluated, the solid dispersion containing Drug, Hydroxy Propyl Cellulose and Compritol 888 ATO at a weight ratio of 1:0.5:0.25 gave optimum controlled release dissolution profiles from 120mg, 240mg and 360mg strength formulations. Thought the amount of drug release was observed to be directly proportional to the dosage strengths, the % drug release vs. time yielded similar graphs, suggesting that dissolution patterns from all strengths are same. But the Physical Mixture of same formulation released 100% of drug in less than 60 minutes suggesting that it is not the polymer alone but the solid dispersion is controlling the drug release. The samples from Enlarged batches and stability studies also exhibited unaltered dissolution profiles from all strengths. The Dissolution data were treated with various kinetic orders and Higuchi's model provided the best fit suggesting that controlled release was diffusion based. The characterization studies indicated that there were no chemical interactions among the formulation ingredients.;Solid dispersion technique proved useful in formulating a single controlled release powder for its direct use in the development of 120mg, 240mg and 360mg dosage forms of Diltiazem Hydrochloride.
机译:盐酸地尔硫卓是一种钙离子细胞内流抑制剂(慢通道阻滞剂或钙拮抗剂)。地尔硫卓通常用于治疗高血压(高血压),心绞痛(胸痛)和某些心律失常的药物。基于各种技术的控释制剂目前可用于一天一次的治疗。进行这项研究以调查应用固体分散法开发该药物控释制剂的可能性。在开发适用于配制多种强度剂型的单一固体分散体粉末时,对各种速率控制聚合物进行了评估。不同的固体分散体是通过溶剂蒸发技术使用单载体系统和多载体系统制备的。根据USP溶出度仪I对相当于120mg,240mg和360mg药物的样品的体外药物释放曲线进行了评估。溶出度研究分别使用SGF和SIF作为溶出介质进行了2小时和24小时。为了比较目的,还包括最佳配方的物理混合物。将分散体样品在各种温度下老化1个月,并评估药物释放。另外,扩大了制剂,并研究了其稳定性以用于商业规模。进行了包括差示扫描量热法,XRD和FTIR在内的物理研究,以表征固体分散体;在所有评估的样品中,以重量比为1:0.5:0.25的比例包含药物,羟丙基纤维素和Compritol 888 ATO的固体分散体120mg,240mg和360mg强度制剂的最佳控释溶出曲线。考虑到观察到的药物释放量与剂量强度成正比,药物释放百分比与时间的关系图类似,表明所有强度的溶出模式均相同。但是相同配方的物理混合物在不到60分钟的时间内释放了100%的药物,这表明它不是单独的聚合物,而是固体分散体控制着药物的释放。扩大批次和稳定性研究的样品还显示出所有强度的不变溶出曲线。溶出度数据采用各种动力学顺序进行处理,Higuchi模型提供了最佳拟合,表明控释是基于扩散的。表征研究表明,制剂成分之间没有化学相互作用。固体分散技术证明可用于配制单一控释粉剂,以直接用于开发盐酸地尔硫卓的120mg,240mg和360mg剂型。

著录项

  • 作者

    Naidu, Srinesh.;

  • 作者单位

    Long Island University, The Brooklyn Center.;

  • 授予单位 Long Island University, The Brooklyn Center.;
  • 学科 Pharmaceutical sciences.
  • 学位 M.S.
  • 年度 2015
  • 页码 132 p.
  • 总页数 132
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:53:05

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号